Tau reduction does not prevent motor deficits in two mouse models of Parkinson's disease

PLoS ONE

Volumn 6, Issue 12, 2011, Pages

  Morris, Meaghan ^a,b   Koyama, Akihiko ^a,e   Masliah, Eliezer ^c   Mucke, Lennart ^a,d  

^a GLADSTONE INSTITUTE OF NEUROLOGICAL DISEASE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e EISAI INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; OXIDOPAMINE; TAU PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE MODEL; DISEASE SEVERITY; DOPAMINERGIC NERVE CELL; MOTOR DYSFUNCTION; MOUSE; NERVE ENDING; NONHUMAN; PARKINSON DISEASE; PROTEIN EXPRESSION; TRANSGENE; TRANSGENIC MOUSE; WILD TYPE; ANIMAL; C57BL MOUSE; GENETICS; HUMAN; METABOLISM; MOTOR ACTIVITY; PATHOPHYSIOLOGY;

ALPHA-SYNUCLEIN; ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MOTOR ACTIVITY; PARKINSON DISEASE; TAU PROTEINS;

EID: 83655181921     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0029257     Document Type: Article

References (52)

1. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, et al. (2005) Global prevalence of dementia: A Delphi consensus study. Lancet 366: 2112-2117.
2. Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, et al. (2007) Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 68: 384-386.
3. Thies W, Bleiler L, (2011) 2011 Alzheimer's disease facts and figures. Alzheimers Dement 7: 208-244.
4. Pearce J, (1974) The extrapyramidal disorder of Alzheimer's disease. Eur Neurol 12: 94-103.
5. Lieberman A, Dziatolowski M, Kupersmith M, Serby M, Goodgold A, et al. (1979) Dementia in Parkinson disease. Ann Neurol 6: 355-359.
6. Leverenz J, Sumi SM, (1986) Parkinson's disease in patients with Alzheimer's disease. Arch Neurol 43: 662-664.
7. Ditter SM, Mirra SS, (1987) Neuropathologic and clinical features of Parkinson's disease in Alzheimer's disease patients. Neurology 37: 754-760.
8. Mayeux R, Stern Y, Rosenstein R, Marder K, Hauser A, et al. (1988) An estimate of the prevalence of dementia in idiopathic Parkinson's disease. Arch Neurol 45: 260-262.
9. Hofman A, Schulte W, Tanja TA, van Duijn CM, Haaxma R, et al. (1989) History of dementia and Parkinson's disease in 1st-degree relatives of patients with Alzheimer's disease. Neurology 39: 1589-1592.
10. Lippa CF, Fujiwara H, Mann DMA, Giasson B, Baba M, et al. (1998) Lewy bodies contain altered α-synuclein in brains of many familiar Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. Am J Pathol 153: 1365-1370.
11. Hamilton RL, (2000) Lewy bodies in Alzheimer's disease: A neuropathological review of 145 cases using α-synuclein immunohistochemistry. Brain Pathol 10: 378-384.
12. Mikolaenko I, Pletnikova O, Kawas CH, O'Brien R, Resnick SM, et al. (2005) α-synuclein lesions in normal aging, Parkinson disease, and Alzheimer disease: Evidence from the Baltimore Longitudinal Study of Aging (BLSA). J Neuropathol Exp Neurol 64: 156-162.
13. Hakim AM, Mathieson G, (1979) Dementia in Parkinson disease: A neuropathologic study. Neurology 29: 1209-1214.
14. Boller F, Mizutani T, Roessmann U, Gambetti P, (1980) Parkinson disease, dementia, and Alzheimer disease: Clinicopathological correlations. Ann Neurol 7: 329-335.
15. Lee VM, Balin BJ, Otvos L Jr, Trojanowski JQ, (1991) A68: a major subunit of paired helical filaments and derivatized forms of normal Tau. Science 251: 675-678.
16. Biernat J, Mandelkow EM, Schroter C, Lichtenberg-Kraag B, Steiner B, et al. (1992) The switch of tau protein to an Alzheimer-like state includes the phosphorylation of two serine-proline motifs upstream of the microtubule binding region. EMBO J 11: 1593-1597.
17. Wills J, Jones J, Haggerty T, Duka V, Joyce JN, et al. (2010) Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson's disease brains with and without dementia. Exp Neurol 225: 210-218.
18. Wills J, Credle J, Haggerty T, Lee JH, Oaks AW, et al. (2011) Tauopathic changes in the striatum of A53T alpha-synuclein mutant mouse model of Parkinson's disease. PLoS One 6: e17953.
19. Grundke-Iqbal I, Iqbal K, Quinlan M, Tung YC, Zaidi MS, et al. (1986) Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem 261: 6084-6089.
20. Wood JG, Mirra SS, Pollock NJ, Binder LI, (1986) Neurofibrillary tangles of Alzheimer disease share antigenic determinants with the axonal microtubule-associated protein tau (τ). Proc Natl Acad Sci USA 83: 4040-4043.
21. Kondo J, Honda T, Mori H, Hamada Y, Miura R, et al. (1988) The carboxyl third of tau is tightly bound to paired helical filaments. Neuron 1: 827-834.
22. Duda JE, Giasson BI, Mabon ME, Miller DC, Golbe LI, et al. (2002) Concurrence of alpha-synuclein and tau brain pathology in the Contursi kindred. Acta Neuropathol 104: 7-11.
23. Kotzbauer PT, Giasson BI, Kravitz AV, Golbe LI, Mark MH, et al. (2004) Fibrillization of alpha-synuclein and tau in familial Parkinson's disease caused by the A53T alpha-synuclein mutation. Exp Neurol 187: 279-288.
24. Rajput A, Dickson DW, Robinson CA, Ross OA, Dachsel JC, et al. (2006) Parkinsonism, Lrrk2 G2019S, and tau neuropathology. Neurology 67: 1506-1508.
25. Kosik KS, Joachim CL, Selkoe DJ, (1986) Microtubule-associated protein tau (τ) is a major antigenic component of paired helical filaments in Alzheimer disease. Proc Natl Acad Sci USA 83: 4044-4048.
26. Pastor P, Ezquerra M, Munoz E, Marti MJ, Blesa R, et al. (2000) Significant association between the tau gene A0/A0 genotype and Parkinson's disease. Ann Neurol 47: 242-245.
27. Golbe LI, Lazzarini AM, Spychala JR, Johnson WG, Stenroos ES, et al. (2001) The tau A0 allele in Parkinson's disease. Mov Disord 16: 442-447.
28. Martin ER, Scott WK, Nance MA, Watts RL, Hubble JP, et al. (2001) Association of single-nucleotide polymorphisms of the tau gene with late-onset Parkinson disease. JAMA 286: 2245-2250.
29. Elbaz A, Ross OA, Ioannidis JP, Soto-Ortolaza AI, Moisan F, et al. (2011) Independent and joint effects of the MAPT and SNCA genes in Parkinson disease. Ann Neurol 69: 778-792.
30. Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, et al. (2007) Reducing endogenous tau ameliorates amyloid β-induced deficits in an Alzheimer's disease mouse model. Science 316: 750-754.
31. Andrews-Zwilling Y, Bien-Ly N, Xu Q, Li G, Bernardo A, et al. (2010) Apolipoprotein E4 causes age- and Tau-dependent impairment of GABAergic interneurons, leading to learning and memory deficits in mice. J Neurosci 30: 13707-13717.
32. Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, et al. (2010) Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell 142: 387-397.
33. Roberson ED, Halabisky B, Yoo JW, Yao J, Chin J, et al. (2011) Amyloid-β/Fyn-induced synaptic, network, and cognitive impairments depend on Tau levels in multiple mouse models of Alzheimer's disease. J Neurosci 31: 700-711.
34. Giasson BI, Forman MS, Higuchi M, Golbe LI, Graves CL, et al. (2003) Initiation and synergistic fibrillization of tau and alpha-synuclein. Science 300: 636-640.
35. Frasier M, Walzer M, McCarthy L, Magnuson D, Lee JM, et al. (2005) Tau phosphorylation increases in symptomatic mice overexpressing A30P alpha-synuclein. Exp Neurol 192: 274-287.
36. Haggerty T, Credle J, Rodriguez O, Wills J, Oaks AW, et al. (2011) Hyperphosphorylated Tau in an alpha-synuclein-overexpressing transgenic model of Parkinson's disease. Eur J Neurosci 33: 1598-1610.
37. Lin CH, Tsai PI, Wu RM, Chien CT, (2010) LRRK2 G2019S mutation induces dendrite degeneration through mislocalization and phosphorylation of tau by recruiting autoactivated GSK3ss. J Neurosci 30: 13138-13149.
38. Shulman JM, De Jager PL, Feany MB, (2011) Parkinson's disease: Genetics and pathogenesis. Annu Rev Pathol 6: 193-222.
39. Matsuura K, Kabuto H, Makino H, Ogawa N, (1997) Pole test is a useful method for evaluating the mouse movement disorder caused by striatal dopamine depletion. J Neurosci Methods 73: 45-48.
40. Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, et al. (2000) Dopaminergic loss and inclusion body formation in α-synuclein mice: Implications for neurodegenerative disorders. Science 287: 1265-1269.
41. Fleming SM, Salcedo J, Fernagut PO, Rockenstein E, Masliah E, et al. (2004) Early and progressive sensorimotor anomalies in mice overexpressing wild-type human α-synuclein. J Neurosci 24: 9434-9440.
42. Fleming SM, Salcedo J, Hutson CB, Rockenstein E, Masliah E, et al. (2006) Behavioral effects of dopaminergic agonists in transgenic mice overexpressing human wildtype α-synuclein. Neuroscience 142: 1245-1253.
43. Dawson HN, Ferreira A, Eyster MV, Ghoshal N, Binder LI, et al. (2001) Inhibition of neuronal maturation in primary hippocampal neurons from tau deficient mice. J Cell Sci 114: 1179-1187.
44. Rockenstein E, Mallory M, Hashimoto M, Song D, Shults C, et al. (2002) Differential neuropathological alterations in transgenic mice expressing α-synuclein from the PDGF-B and Thy-1 promoters. J Neurosci Res 68: 568-578.
45. Guyenet SJ, Furrer SA, Damian VM, Baughan TD, La Spada AR, et al. (2010) A simple composite phenotype scoring system for evaluating mouse models of cerebellar ataxia. J Vis Exp.
46. Fernagut PO, Hutson CB, Fleming SM, Tetreaut NA, Salcedo J, et al. (2007) Behavioral and histopathological consequences of paraquat intoxication in mice: Effects of alpha-synuclein over-expression. Synapse 61: 991-1001.
47. Rapoport M, Dawson HN, Binder LI, Vitek MP, Ferreira A, (2002) Tau is essential to β-amyloid-induced neurotoxicity. Proc Natl Acad Sci USA 99: 6364-6369.
48. King ME, Kan HM, Baas PW, Erisir A, Glabe CG, et al. (2006) Tau-dependent microtubule disassembly initiated by prefibrillar β-amyloid. J Cell Biol 175: 541-546.
49. Vossel KA, Zhang K, Brodbeck J, Daub AC, Sharma P, et al. (2010) Tau reduction prevents Aβ-induced impairments in axonal transport. Science 330: 198.
50. Hammond C, Bergman H, Brown P, (2007) Pathological synchronization in Parkinson's disease: networks, models and treatments. Trends Neurosci 30: 357-364.
51. Gittis AH, Hang GB, LaDow ES, Shoenfeld LR, Atallah BV, et al. (2011) Rapid target-specific remodeling of fast-spiking inhibitory circuits after loss of dopamine. Neuron 71: 858-868.
52. Lam HA, Wu N, Cely I, Kelly RL, Hean S, et al. (2011) Elevated tonic extracellular dopamine concentration and altered dopamine modulation of synaptic activity precede dopamine loss in the striatum of mice overexpressing human alpha-synuclein. J Neurosci Res 89: 1091-1102.